避免过度化疗或化疗不足

明达实业股份有限公司 23450 新北市永和区福和路389号9楼

NCCN更新治疗指引，将MammaPrint纳入乳癌检测1级美国国家癌症资讯网(NCCN)和美国临床肿瘤医学会(ASCO)针对lymph-node positive患者，更新的NCCN治疗指引中推荐的唯一基因组乳癌检测工具美国国家癌症资讯网(NCCN)更新治疗指引，将MammaPrint纳入乳癌检测1级NCCN推荐Agendia的MammaPrint为高水平的乳癌检测，对於早期乳癌患者ER+，lymph-node negative和lymph-node positive（LN+1-3）MammaPrint现在是美国国家癌症资讯网(NCCN)和美国临床肿瘤医学会(ASCO)针对lymph-node positive患者，更新的NCCN治疗指引中推荐的唯一基因组乳癌检测工具。Agendia的公司今天宣布，美国国家癌症资讯网(NCCN)更新了其临床实践治疗指引为包括MammaPrint 70-基因乳癌复发风险测试，有助於确定乳癌在lymph-node negative或positive(LN + 1-3)的ER+乳癌患者中复发的可能性。通过这些更新，MammaPrint获得了基因组测试的最广泛指导，具并且是同类测试中唯一具有1级的lymph-node negative和lymph-node positive疾病证据的检测。NCCN美国国家癌症资讯网(National Comprehensive Cancer Network)治疗指引是公认的癌症治疗临床标准，是由领先的癌症中心的临床医生和研究人员提供的。NCCN根据现有证据修订推荐的实践治疗指引，最终目标是改善患者护理和结果。MammaPrint纳入NCCN治疗指引是基於具有里程碑意义的临床试验MINDACT的数据，这是一项随机，前瞻性的III期试验，评估了MammaPrint试验的临床效用。该研究於2016年发表在“ New England Journal of Medicine”上，发现近50％的患者最初根据临床和病理因素确定其癌症复发风险高，因此而接受化疗的患者实际上是低风险的。MammaPrint分析了与乳癌复发相关的70个最关键的基因，将每个乳癌患者分类为诊断后早期10年内发生转移的“低风险”或“高风险”。您可以访问www.nccn.org查看NCCN更新的治疗指引。Agendia Announces Level 1 Inclusion of MammaPrint® Breast Cancer Test in Updated National Comprehensive Cancer Network® (NCCN) GuidelinesAgendia Announces Level 1 Inclusion of MammaPrint® Breast Cancer Test in Updated National Comprehensive Cancer Network® (NCCN) GuidelinesThe NCCN recommends Agendia’s MammaPrint® breast cancer test with the highest level of evidence for early-stage breast cancer patients with estrogen receptor-positive, lymph-node negative and lymph-node positive (LN+ 1-3) MammaPrint is now the only genomic breast cancer test that is recommended in guidelines by the NCCN and the American Society of Clinical Oncology (ASCO) for lymph-node positive patients The updated NCCN Guidelines – released during Breast Cancer Awareness Month– mark the fifth positive international guideline update for MammaPrint since 2017IRVINE, CALIF., U.S., AMSTERDAM, NETHERLANDS – 9 October 2018 – Agendia, Inc., a world leader in precision oncology, today announced that the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines to include the MammaPrint® 70-gene Breast Cancer Risk-of-Recurrence Test, which helps determine the likelihood breast cancer will recur in patients with estrogen receptor-positive breast cancer that is either lymph-node negative or positive (LN+ 1-3). With these updates, MammaPrint has received the broadest guidance of any genomic test, and is the only test of its kind with Level 1 evidence for both lymph-node negative and lymph-node positive disease.The NCCN Guidelines, which are the recognized clinical standard for cancer care, are created by input from clinicians and researchers at leading cancer centers. The NCCN revises recommended practice guidelines according to current evidence with the ultimate goal of improving patient care and outcomes.MammaPrint’s inclusion in the NCCN guidelines is based on data from the landmark clinical trial, MINDACT, a randomized, prospective, Phase III trial, which evaluated the clinical utility of the MammaPrint test. The study, published in the New England Journal of Medicine in 2016, found that almost 50 percent of patients initially identified with a high risk of their cancer recurring based on clinical and pathological factors and thus candidates for chemotherapy, were in fact Low Risk according to the MammaPrint test and unlikely to benefit from it.MammaPrint analyzes the 70 most important genes associated with breast cancer recurrence to classify each breast cancer patient into “Low Risk” or “High Risk” of developing metastases within the first 10 years after diagnosis.You can access the updated NCCN guidelines at www.nccn.org. http://www.ybe.com.tw/hot_293657.html NCCN更新治疗指引，将MammaPrint纳入乳癌检测1级 │ 美国国家癌症资讯网(NCCN)和美国临床肿瘤医学会(ASCO)针对lymph-node positive患者，更新的NCCN治疗指引中推荐的唯一基因组乳癌检测工具 2022-09-06 2023-09-06

明达实业股份有限公司 23450 新北市永和区福和路389号9楼 http://www.ybe.com.tw/hot_293657.html

明达实业股份有限公司 23450 新北市永和区福和路389号9楼 http://www.ybe.com.tw/hot_293657.html

https://schema.org/EventMovedOnline https://schema.org/OfflineEventAttendanceMode

2022-09-06 http://schema.org/InStock TWD 0 http://www.ybe.com.tw/hot_293657.html

首页了解 MammaPrint+BluePrint 欣扶你乳癌肿瘤基因双效检测国际许可及认证资格列入ASCO《临床实践指南》│ ASCO临床实践指南发表了题为“Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer”使用生物标志对早期浸润性乳癌妇女的全身性辅助治疗决策指引

MammaPrint+BluePrint欣扶你乳癌肿瘤基因双效检测
列入ASCO美国临床肿瘤学会《临床实践指南》

ASCO(American Society of Clinical Oncology)美国临床肿瘤学会於2017年7月10日，在《临床实践指南》发表了题为“Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer”使用生物标志对早期浸润性乳癌妇女的全身性辅助治疗决策指引，再次肯定了MINDACT试验的临床应用价值，您可经由下列ASCO网站连结一睹最新聚焦亮点：

ASCO(American Society of Clinical Oncology)美国临床肿瘤学会发表：https://www.asco.org/practice-guidelines/quality-guidelines/guidelines/breast-cancer#/9746

JCO(Journal of clinical oncology)临床肿瘤学杂志亦同步发表：http://ascopubs.org/doi/full/10.1200/JCO.2017.74.0472

ASCO推荐ER/PgR–positive, HER2-negative, node-negative, or one to three positive nodes临床高危险群病患，使用MammaPrint可进行化疗必要性之决定。

其中针对one to three positive nodes病患群，可谓是MINDACT带来的患者福音，也是唯一ASCO推荐之高水准MammaPrint基因组测试。

上一个回列表下一个